Integra LifeSciences Holdings Corporation (NASDAQ:IART)‘s stock had its “buy” rating reissued by Jefferies Group LLC in a research report issued on Sunday.

A number of other brokerages also recently commented on IART. BidaskClub downgraded Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Oppenheimer Holdings, Inc. set a $60.00 price objective on Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research report on Saturday, June 24th. Cantor Fitzgerald assumed coverage on Integra LifeSciences Holdings Corporation in a research report on Thursday, June 29th. They set an “overweight” rating and a $65.00 price objective on the stock. Zacks Investment Research downgraded Integra LifeSciences Holdings Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, June 28th. Finally, UBS AG reiterated a “buy” rating and set a $60.00 price objective (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Friday, June 9th. Five equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $52.63.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at 52.14 on Friday. The company’s 50-day moving average price is $50.52 and its 200 day moving average price is $48.03. The stock has a market cap of $4.07 billion, a price-to-earnings ratio of 63.59 and a beta of 0.73. Integra LifeSciences Holdings Corporation has a 12-month low of $40.51 and a 12-month high of $88.33.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The firm had revenue of $282.16 million for the quarter, compared to the consensus estimate of $283.58 million. During the same quarter last year, the business posted $0.40 earnings per share. The firm’s revenue was up 13.2% compared to the same quarter last year. On average, equities analysts predict that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Integra LifeSciences Holdings Corporation (IART) Earns Buy Rating from Jefferies Group LLC” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/09/10/integra-lifesciences-holdings-corporation-iart-earns-buy-rating-from-jefferies-group-llc.html.

In other Integra LifeSciences Holdings Corporation news, Director Donald E. Morel, Jr. bought 2,500 shares of Integra LifeSciences Holdings Corporation stock in a transaction on Thursday, August 3rd. The shares were bought at an average price of $49.29 per share, for a total transaction of $123,225.00. Following the completion of the transaction, the director now directly owns 29,612 shares of the company’s stock, valued at $1,459,575.48. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Barbara B. Hill bought 5,050 shares of Integra LifeSciences Holdings Corporation stock in a transaction on Tuesday, August 1st. The stock was acquired at an average price of $49.33 per share, for a total transaction of $249,116.50. Following the transaction, the director now directly owns 44,772 shares of the company’s stock, valued at $2,208,602.76. The disclosure for this purchase can be found here. Insiders acquired 17,550 shares of company stock worth $864,842 in the last 90 days. Company insiders own 21.50% of the company’s stock.

Large investors have recently bought and sold shares of the business. Acrospire Investment Management LLC raised its position in Integra LifeSciences Holdings Corporation by 280.0% in the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after purchasing an additional 1,400 shares during the period. Riverhead Capital Management LLC raised its holdings in shares of Integra LifeSciences Holdings Corporation by 49.9% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after buying an additional 799 shares during the period. LS Investment Advisors LLC raised its holdings in shares of Integra LifeSciences Holdings Corporation by 90.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,412 shares of the life sciences company’s stock valued at $102,000 after buying an additional 1,147 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Integra LifeSciences Holdings Corporation by 223.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock valued at $107,000 after buying an additional 1,751 shares during the period. Finally, Turner Investments LLC purchased a new stake in shares of Integra LifeSciences Holdings Corporation in the 1st quarter valued at $126,000. Institutional investors own 85.28% of the company’s stock.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.